Andrew Hirsch

2017 - Agios Pharmaceuticals

In 2017, Andrew Hirsch earned a total compensation of $2.3M as Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals, a 56% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$217,537
Option Awards$1,639,353
Salary$453,201
Other$9,964
Total$2,320,055

Hirsch received $1.6M in option awards, accounting for 71% of the total pay in 2017.

Hirsch also received $217.5K in non-equity incentive plan, $453.2K in salary and $10K in other compensation.

Rankings

In 2017, Andrew Hirsch's compensation ranked 4,798th out of 14,666 executives tracked by ExecPay. In other words, Hirsch earned more than 67.3% of executives.

ClassificationRankingPercentile
All
4,798
out of 14,666
67th
Division
Manufacturing
1,701
out of 5,768
71st
Major group
Chemicals And Allied Products
502
out of 2,074
76th
Industry group
Drugs
387
out of 1,730
78th
Industry
Pharmaceutical Preparations
307
out of 1,329
77th
Source: SEC filing on April 18, 2018.

Hirsch's colleagues

We found four more compensation records of executives who worked with Andrew Hirsch at Agios Pharmaceuticals in 2017.

2017

David Schenkein

Agios Pharmaceuticals

Chief Executive Officer

2017

Christopher Bowden

Agios Pharmaceuticals

Chief Medical Officer

2017

Scott Biller

Agios Pharmaceuticals

Chief Scientific Officer

2017

Steve Hoerter

Agios Pharmaceuticals

Chief Commercial Officer

News

In-depth

You may also like